BFM
CCCC icon

Boothbay Fund Management’s C4 Therapeutics CCCC Stock Holding History

Boothbay Fund Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Buy
+736,331
New +$2.52M 0.05% 470
2024
Q1 		– Sell
-13,400
Closed -$75.7K – 1600
2023
Q4 		$75.7K Buy
+13,400
New +$30.6K ﹤0.01% 1470
2021
Q2 		– Sell
-12,026
Closed -$445K – 1871
2021
Q1 		$445K Sell
12,026
-4,178
-26% -$166K 0.02% 997
2020
Q4 		$537K Buy
+16,204
New +$470K 0.02% 717

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boothbay Fund Management's CCCC Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 736,331 shares worth $3.44M. The stake represents 0.05% of the portfolio and ranks #470 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in CCCC as recently as Q4 2023.

Boothbay Fund Management first reported a position in CCCC in Q4 2020 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Boothbay Fund Management held 736,331 shares of C4 Therapeutics worth $3.44M as of Q2 2026.
  • C4 Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • C4 Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #470 holding.
  • Boothbay Fund Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.